HT update: spotlight on estradiol/norethindrone acetate combination therapy | Zendy

Colleen Casey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HT update: spotlight on estradiol/norethindrone acetate combination therapy

Author(s) -

Colleen Casey

Publication year - 2008

Publication title -

clinical interventions in aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.184

H-Index - 76

eISSN - 1178-1998

pISSN - 1176-9092

DOI - 10.2147/cia.s1663

Subject(s) - medicine , estrogen , progestin , hormone replacement therapy (female to male) , hormone therapy , estrogen replacement therapy , postmenopausal women , estrogen therapy , combination therapy , medroxyprogesterone acetate , norethisterone acetate , norethisterone , gynecology , population , health services , cancer , breast cancer , environmental health , testosterone (patch)

The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research